Insurer stops covering HIV prevention drug

Health insurer Pacific Blue Cross is no longer covering a controversial medication that can prevent the spread of HIV, the virus that leads to AIDS.

Letters went out in late April to fewer than 10 people who had been receiving $900 per month in extended health coverage for the once-a-day pill called Truvada, confirmed Joanne Jung, director of pharmacy services for the not-for-profit insurer. The letters said Blue Cross paid for the medication in error and later determined it is not eligible as a pre-exposure prophylaxis or PrEP under the contracts in question.

The drug, which combines two anti-viral agents, was originally developed to treat HIV infections, but was approved by Health Canada in February as a preventive measure when taken by people who do not have HIV but are exposed to it through sex. Some doctors earlier prescribed it for that purpose on an off-label basis.

When used for prevention, Truvada is considered a supplemental drug – as are birth control pills, vaccines, and medications to enhance sexual function – and are not covered under all drug plans, Blue Cross says.

“We sincerely apologize if the letter created any confusion for those members,” Jung added in an emailed statement.

Douglas McClelland, 61, says he took the medication for 18 months, covered by his extended health care plan with Blue Cross, because his partner is HIV positive.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below